Mölndal, Sweden – 7 June 2016 – Cellectricon AB, a leading provider of advanced cell-based Discovery Services, today announced a commercial collaboration with UK-based research company Neurexpert Ltd. Under the agreement, Cellectricon and Neurexpert will co-promote their combined CNS drug discovery expertise, with a particular focus on synaptic function assays, for research into treatments of central nervous system disorders in the fields of psychiatry, neurology, pain and neurodegeneration.
“As a provider of specialist neurophysiology expertise and with over 80 years combined experience in developing electrophysiological assays to test the action of novel compounds on neuronal synaptic function, we are very excited about this collaboration with Cellectricon,” said Neurexpert co-founder Professor Tom Salt. “With our extensive CNS expertise, we believe that we provide important domain knowledge that adds further value to Cellectricon’s proprietary Cellaxess® Elektra Discovery Services screening platform and expert scientific staff”.
“Through our collaboration with Neurexpert, we have further enhanced our Discovery Services offering for CNS research”, said Cellectricon’s VP Commercial & Technology, Mattias Karlsson. “The additional range of complementary cell-based assays that bridge the gap between in vitro and in vivo screens provides assurance that potency and selectivity data translate into physiologically-relevant activity, thereby confirming mechanism of action. Being able to access the information-rich assays and specialist expertise of the Neurexpert team gives essential functional and mechanistic validation to complement and expand our Discovery Services techniques – a real value-add for our clients”.
For more information on Cellectricon’s Pain and CNS Discovery Services, please visit the Discovery Services Page: www.cellectricon.com
About Neurexpert (www.neurexpert.com):
Neurexpert was founded in 2011 by Dr Stuart Neale and Professor Tom Salt. The company provides assays delivering data on compound potency and efficacy at the native target, confirming mechanism of action and giving essential functional and mechanistic data on the neural mechanisms underlying higher brain functions. The company assists project progression at all stages of the drug discovery process, from target validation and early stage screening through to functional biomarker studies to aid clinical development.
